Final Evidence Report and Meeting Summary
New England CEPAC

PDF cover

This is not the most recent version of this material.
For an updated version, please see the relevant topic page.

High Cholesterol: Final Report

In September of 2017, ICER release a New Evidence Update that reviewed newly available data on evolocumab and provided an updated value-based price benchmark for that drug.


This report examines the comparative effectiveness and value of drug therapies for the management of high cholesterol, including two PCSK9 inhibitors: alirocumab (Praluent®, Sanofi and Regeneron Pharmaceuticals, Inc.) and evolocumab (RepathaTM, Amgen). It includes a systematic review of the published evidence, as well as an economic analysis that examines cost-effectiveness and budget impact of the drugs. The results of these analyses are used to produce an ICER value-based price benchmark for each intervention; these are prices that reflect the magnitude of estimated improvements in long-term patient outcomes and thresholds for new drug and device costs that do not exceed growth in the overall national economy.


View All Materials on this Topic or Go Back to View More Materials